Aprea Therapeutics, Inc.
APRE
$0.79
$0.000.01%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -90.41% | -80.99% | -62.76% | -34.08% | 33.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -90.41% | -80.99% | -62.76% | -34.08% | 33.26% |
| Cost of Revenue | -39.77% | -24.78% | -7.26% | 15.31% | 28.54% |
| Gross Profit | 32.51% | 14.04% | -2.14% | -24.24% | -27.89% |
| SG&A Expenses | 3.77% | 0.28% | -15.90% | -15.50% | -9.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.20% | -14.55% | -11.03% | 1.08% | 10.54% |
| Operating Income | 17.55% | 7.58% | 6.44% | -4.24% | -8.97% |
| Income Before Tax | 15.10% | 2.77% | 3.47% | -7.13% | -10.73% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 15.10% | 2.77% | 3.47% | -7.13% | -10.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.10% | 2.77% | 3.47% | -7.13% | -10.73% |
| EBIT | 17.55% | 7.58% | 6.44% | -4.24% | -8.97% |
| EBITDA | 17.57% | 7.59% | 6.45% | -4.22% | -8.92% |
| EPS Basic | 34.76% | 16.94% | 23.87% | 23.79% | 28.85% |
| Normalized Basic EPS | 34.76% | 16.93% | 23.86% | 23.79% | 28.85% |
| EPS Diluted | 34.87% | 16.77% | 23.73% | 23.66% | 28.73% |
| Normalized Diluted EPS | 34.76% | 16.93% | 23.86% | 23.79% | 28.85% |
| Average Basic Shares Outstanding | 46.19% | 18.65% | 23.18% | 36.14% | 54.69% |
| Average Diluted Shares Outstanding | 46.19% | 18.65% | 23.18% | 36.14% | 54.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |